TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Prevention of Seroma Following Inguinal Lymph Node Dissection With Prophylactic Incisional Negative Pressure Wound Therapy
Brief Summary: Inguinal lymph node dissection (ILND) is indicated following metastatic malignant melanoma, and is associated with a high-complication rate, of which many begin with the formation of seroma and ends in complicated wound healing, reoperation, multiple outpatient visits and re-hospitalization. Prevention of seroma may therefore lead to a reduction of many of the preceding complications and improve patient quality-of-life. The aim of this study is to evaluate the efficacy and oncological safety of prophylactic negative pressure wound therapy following ILND in melanoma patients.


Options:
A: Key inclusion criteria BMI greater than or equal to 30 kg/m2 at less than or equal to 22 weeks of gestation Subject is laboring Subject is having an unplanned cesarean section Subject will have Pfannenstiel Skin Incision Subject has the ability to take a picture and email it to a secure account Subject receives prenatal care in the University of Pennsylvania health system and plans to follow up postpartum in the system Subject is greater than or equal to 18 years of age

Key exclusion criteria Subject cannot read or speak English Subject is not 18 years of age Subject does not have ability to send a picture by email Subject has preexisting diabetes mellitus (Type 1 or Type 2) , is using chronic steroids or immune-suppressants, OR being actively treated for a malignancy Subject is undergoing a scheduled cesarean section Subject is allergic to silver
B: Inclusion Criteria:

* patients presenting to wound center undergoing wound treatment with expected closure of wounds including: Midfoot amputations, below knee amputations, knee disarticulations, above knee amputations, and trunk wounds
* wounds must be closed primarily without the use of grafts

Exclusion Criteria:

* any patient \<18 years old
* any patient whose wound is unable to be closed primarily
C: Inclusion Criteria:

* All malignant melanoma patients who are candidates for ILND and 18 years of age or older

Exclusion Criteria:

* Patients suspected of having tumor residuals after ILND, previous groin irradiation or patients suffering from dementia or any psychiatric disorder making them incapable of informed consent or adherence to follow up, along with patients who are unable to communicate in Danish or English will not be included in the study.
D: Inclusion Criteria:

* BMI \> 35
* Previous femoral exposure
* Undergoing lower-limb revascularization

Exclusion Criteria:

* Cannot obtain seal
* Non-primary wound closure
* Pre-existing infection
* Endovascular repair

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Prevention of Seroma Following Inguinal Lymph Node Dissection With Prophylactic Incisional Negative Pressure Wound Therapy
Brief Summary: Inguinal lymph node dissection (ILND) is indicated following metastatic malignant melanoma, and is associated with a high-complication rate, of which many begin with the formation of seroma and ends in complicated wound healing, reoperation, multiple outpatient visits and re-hospitalization. Prevention of seroma may therefore lead to a reduction of many of the preceding complications and improve patient quality-of-life. The aim of this study is to evaluate the efficacy and oncological safety of prophylactic negative pressure wound therapy following ILND in melanoma patients.


Options:
A: Inclusion Criteria:

* All malignant melanoma patients who are candidates for ILND and 18 years of age or older

Exclusion Criteria:

* Patients suspected of having tumor residuals after ILND, previous groin irradiation or patients suffering from dementia or any psychiatric disorder making them incapable of informed consent or adherence to follow up, along with patients who are unable to communicate in Danish or English will not be included in the study.
B: Inclusion Criteria:

* Patients over 18 years old (men and women).
* To give his consent to participation in the study.
* To have surgical prosthetic repair of large incisional hernia (type W2 or W3).
* Patients admitted to the 6th floor, G tower (Unit of Abdominal Wall surgery).

Exclusion Criteria:

* Patients with immediate reintervention of abdominal surgery (less than 30 days from the first surgery).
* Patients after emergency surgery.
* Patients with biological prosthesis.
* Pregnancy and lactation.
* Hepatic cirrhosis.
C: Inclusion Criteria:

* Written informed consent
* Coronary heart disease patients to transplant more than 2 vascular bridge
* The thigh groin following from the saphenous vein

Exclusion Criteria:

* Subjects does not agree to participate in clinical trials
* Subjects had a injury, operation history of Thigh
* Subjects having ever received chemotherapy before the surgery
* Subjects with known hypersensitivity to components of the surgical sticky membrane
D: Inclusion Criteria:

* All patients over the age of 18 years of age undergoing a laparotomy are eligible for entry into this study. Benign and malignant conditions are eligible for inclusion.

Exclusion Criteria:

* Pregnant patients and those undergoing re-look laparotomies are to be excluded.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Piloting At-birth Point of Care HIV Testing Strategies in Kenya
Brief Summary: Innovative strategies to expedite HIV diagnosis among exposed infants, including at-birth testing and two portable point-of-care (POC) diagnostic systems, will be piloted using an implementation framework. The programmatic impact of these tools on early infant diagnosis (EID) will be measured in comparison with parallel standard of care (SOC) HIV DNA PCR testing initiated at 6 weeks of age.


Options:
A: Inclusion Criteria:

* Born to HIV positive mother
* From 4 weeks to 18 months of age
* Came to CCR consultation for Early Infant Diagnosis

Exclusion Criteria:

* With a valid positive test by other center
B: Inclusion Criteria:

* Primary Healthcare clinics located in rural and semi-rural settings

Exclusion Criteria:

* Primary Healthcare clinics located in urban settings
C: Inclusion Criteria:

1. Voluntary and informed consent of the mother for her own study participation (if applicable).
2. Voluntary and informed consent of the legal guardian of the child for participation of the child in the study.
3. Mothers/legal guardians ≥18 years of age.
4. Documented maternal HIV infection.
5. Willingness to consent to HIV testing for the child and herself (if applicable).
6. Willing to consent to active tracing including home tracing.

Exclusion Criteria:

1. Deficiency in the mother, rendering it difficult, if not impossible, for her or her infant to take part in the study or understand the information provided to her. This includes alcoholism, drug dependency as well as psychiatric illnesses, suicidal tendencies or any other inability.
2. Having delivered more than 48h ago
3. Prisoners
4. Women presenting with an emergency requiring immediate medical assistance if not resolved at study inclusion.
5. Stillbirths
6. Infant requiring emergency care or born with severe malformation.
7. If within the discretion of the investigator based on recommendation of the gynaecologist or paediatrician in charge study participation would possibly add not acceptable risk or burden to the mother or infant (e.g. significant congenital malformation, health deficiencies, very low birth weight less than 1500g)
8. Unlikely to comply with protocol as judged by the principal investigator or his designate
D: Inclusion Criteria:

* HIV-positive pregnant women enrolled in PMTCT services or who deliver at the study hospitals and/or mothers with exposed infants presenting for EID prior to 24 weeks
* Provide informed consent

Exclusion Criteria:

* HIV-positive pregnant women less than 18 years of age
* HIV-positive pregnant women unable to provide informed consent
* HIV-exposed infants presenting for HIV testing at \> 24 weeks

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Active School. A School-based Intervention to Increase Childrens Daily Physical Activity and Its Effect on Childrens Self-regulation
Brief Summary: This study seeks to explore whether increased physical activity in school affects children's executive function, aerobic Fitness and childrens self-regulation. The "Active school" study was a 10-month randomized controlled trial. The sample included 449 children (10-11 years old) in five intervention and four control schools. The weekly interventions were 2×45 minutes physically active academic lessons, 5×10 minutes physically active breaks, and 5×10 minutes physically active homework. Aerobic fitness was measured using a 10-minute interval running test. Executive function was tested using four cognitive tests (Stroop, verbal fluency, digit span, and Trail Making). A composite score for executive function was computed and used in analyses.

Self-regulation was measured by the Child Behavior Rating Scale.


Options:
A: Inclusion Criteria:

* all children attending 5th grade at the included schools in Stavanger, Norway during the school-year 2014/2015.

Exclusion Criteria:

* not able to participate in daily physical activity and physical education and complete the cognitive tests.
B: Inclusion Criteria:

* Schoolchildren
* Aged 9 to 11 years

Exclusion Criteria:

- no exclusion criteria
C: Inclusion Criteria:

Children participants 3rd or 4th grade student in participating school (during first school year of study)

Exclusion Criteria:

Not a 3rd or 4th grade student
D: Inclusion Criteria:

* 2nd and 3rd grade students

Exclusion Criteria:

* Students who are confined to a wheel chair, blind, or intellectually disadvantaged may be unable perform tests for cardiovascular fitness or MVPA using accelerometers

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomized Controlled Trial of Antibiotic Prophylaxis in Rectal Cancer Surgery: Oral With Intravenous Versus Intravenous Antibiotics.
Brief Summary: This is a randomized, controlled, parallel study to determine the efficiency of oral antibiotics in reduction of surgical site infection (SSI) in rectal cancer surgery.


Options:
A: Inclusion Criteria:

* Patients undergoing colon resection

Exclusion Criteria:

* Emergency surgery needed
* Bowel obstruction
* Colonoscopy scheduled to be undertaken peroperatively
* Other reason indicating mechanical preparation or contradicting it
* Allergy to used drugs (PEG, neomycin, metronidazole)
B: Inclusion Criteria:

The main inclusion criterion was elective colorectal surgery with primary anastomosis

Exclusion Criteria:

Exclusion criteria were an acute laparotomy, laparoscopic colorectal surgery, contraindications for the use of mechanical bowel preparation, an a priori deviating (ileo) stoma, and age less than 18 years old.
C: Inclusion Criteria:

* Patients undergoing ileocolic resections, partial and total colectomies, and rectal resections for neoplasm, inflammatory bowel disease, or diverticulitis
* Subjects with the mental capacity to give informed consent

Exclusion Criteria:

* Patients undergoing emergent colorectal resections
* Patients who are decisionally-impaired and lack the mental capacity to give informed consent
D: Inclusion Criteria:

* Have a planned of resection of rectum
* Have signed approved informed consent form for the study.

Exclusion Criteria:

* Significant simultaneous surgical procedure (e.g., liver resection of metastasis)
* Bacterial infection at the time of surgery or antimicrobial therapy up to 4 weeks before surgery
* Preoperative severe impairment in renal function (creatinine clearance (MDRD) \< 30 ml/min)
* Allergy on the study drugs .

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Impact of Pharmacotherapeutic Education on Medication Adherence and Adverse Outcomes in Type 2 Diabetes Mellitus Patients: Prospective, Randomized Study
Brief Summary: Type 2 diabetes mellitus (T2DM) is a chronic progressive disease that affects more than 400 million people worldwide. There are a few studies evaluating ADRs in diabetics. Many patients experience ADRs soon after hospital discharge which can be attributed to the changes in the pharmacotherapy during hospitalization. Education and counseling of diabetic patients has been shown to improve medication adherence and clinical outcomes. Studies that included medical patients revealed that education can significantly reduce risk of ADRs after hospital discharge. Pharmacotherapeutic education is a part of comprehensive education of diabetics that is focused on a proper use of medications, prevention and early detection of ADRs.


Options:
A: Inclusion Criteria:

* Patient with ST-elevation myocardial infarction (STEMI)
* Treatment with either primary or rescue PCI
* Zwolle risk score \<= 3

Exclusion Criteria:

* Developed MI while in hospital for another reason
* Time from angioplasty to enrollment \> 24 hours
B: Inclusion Criteria:

* Age 65 or over
* Discharged from the UNC emergency department

Exclusion Criteria:

* In the hospital at the time of phone call follow-up
* Neither the patient nor their responsible party are able to pass a standardized test to assess cognitive function
C: Inclusion Criteria:

* age 18 years or older,
* diagnosis of T2DM and
* hospital discharge to the community.

Exclusion Criteria:

* cognitive disorders that would interfere with patient's participation,
* diagnosis of a terminal illness with a life expectancy \<1 month,
* discharge to a long-term care facility or
* inability to be followed-up.
D: Inclusion Criteria:

1. Self-identified as a first generation Korean American
2. Type 2 diabetes
3. Age 30-75 years
4. Resides in Washington-Baltimore area
5. Self-identified with DM and HbA1c \>= 7.0 % within 6 months of screening
6. Expresses willingness to participate in all aspects of the study over its full course

Exclusion Criteria:

1. Unable to give informed consent
2. Physical or mental health conditions that could limit active participation in the study (e.g., blindness in both eyes, severe immobility, psychiatric diseases)
3. Hematological condition that would affect A1C assay, e.g., hemolytic anemia, sickle cell anemia
4. Past experience in diabetes group education

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Use fo Antiseptic Solution for Vaginal Wash Before Cesarean Section in Patients With Premature Rupture of Membranes. A Randomized, Double Blind, Controlled Trial.
Brief Summary: To evaluate the rate of infections after cesarean sections in patients with premature rupture of membranes after vaginal wash either with an antiseptic solution (clorhexidine solution) vs. saline solution (placebo).


Options:
A: Inclusion Criteria:

* Women with gestation between 34 and 41 6/7 weeks.
* Premature rupture of membranes (\> 6 hours).
* Use of prophylactic antibiotic 1 hour previous to cesarean section.

Exclusion Criteria:

* Any source of infection diagnosed previous to surgery.
* Fever of unknown origin previous to surgery.
B: Inclusion Criteria:

* cesarean delivery
* age 18-65
* ability to consent in English or Spanish

Exclusion Criteria:

* inability or unwillingness to consent to study participation in English or Spanish
* current incarceration
* pre-operative diagnosis of chorioamnionitis
* perceived inability to complete follow up for data collection
* any prior known allergy or adverse reaction to either study preparation
C: Intervention Group (vaginal preparation)

Inclusion Criteria:

* Pregnant women admitted for cesarean delivery
* Gestational age greater than or equal to 34 weeks

Exclusion Criteria:

* Rupture of membranes or active labor
* Chorioamnionitis (prior to enrollment)
* Recent (within 4 weeks) antibiotic exposure
* Maternal HIV infection or immunocompromised state
* Known allergy to shellfish, iodine, or chlorhexidine
D: Inclusion Criteria:

* Women undergoing cesarean delivery after labor at Barnes-Jewish Hospital.

Exclusion Criteria:

* Inability to obtain consent
* known or suspected allergy to iodine or shellfish
* women with active herpes simplex virus infection

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Silver Diamine Fluoride Versus Therapeutic Sealants for the Arrest and Prevention of Dental Caries in Low-income Minority Children
Brief Summary: Dental caries (tooth decay) is the most prevalent childhood disease in the world. Multiple interventions are available to treat and prevent caries. The aim of the proposed study is to compare the benefit of silver diamine fluoride (SDF) and fluoride varnish versus fluoride varnish and glass ionomer sealants. This study is a five-year, cluster randomized, pragmatic controlled trial conducted in public elementary schools in New York City.


Options:
A: Inclusion Criteria:

* Any primary school in New York City with a Hispanic/Latino student population greater than 50% and,
* A low-income population (defined as a student receiving free or reduced price lunch) of at least 80%.
* Within participating schools, all children are eligible to participate in the study.

Exclusion Criteria:

* Schools that already have a pre-existing school-based dental health program.
* Within participating schools, exclusion criteria for children include those without informed consent or those with consent but without assent.
B: Inclusion Criteria:

* patients ≥ nine years old;
* permanent molars with primary deep caries lesion reaching dentine inner half (radiographic exam);
* pulpal sensibility positive (cold test);
* absence of spontaneous pain;
* absence of periapical alterations (radiographic exam);
* negative percussion test.

Exclusion Criteria:

* subjects with general diseases affecting their caries experience;
* caries lesion evolving an entire cusp;
* caries lesion with cervical margin in dentine.
C: Inclusion Criteria:

* To have at least one ICDAS 3 lesion in first permanent molars
* To be systemically healthy

Exclusion Criteria:

* Not fully erupted first molars
* Structural defects in first molars, i.e., hypoplasia, fluorosis, MIH.
* Periodontal disease
* Orthodontic appliances
* Medication use
D: Inclusion Criteria:

- Children aged 3-8 years who attend the Preventive and Paediatric Department of Greifswald University, Germany.

(Lithuania: children who attend the paediatric dentistry department, Dental Faculty, Lithuanian University of Health Sciences)

* At least one primary molar tooth with caries into dentine involving two dental surfaces (diagnosed according to the International Caries Detection and Assessment System \[ICDAS\], codes 3 to 5)
* Willing to be examined

Exclusion Criteria:

* Clinical or radiographic signs of pulpal or peri-radicular pathology
* Patients with a systemic disease requiring special considerations during their dental treatment.
* Parents/children who refuse to participate in the study

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Follow-up of Patients Treated in VeClose Study (Five Years)
Brief Summary: The VeClose Five Year Follow-up Extension Study will seek to gain additional follow-up data from the patients enrolled in the VeClose study (NCT01807585).


Options:
A: Inclusion Criteria:

* Primary, symptomatic, varicose veins.
* Isolated Saphenofemoral junction (SFJ) incompetence leading to long saphenous (LSV) reflux on duplex ultrasound.
* LSV of 4mm diameter at the knee.
* Ability to give informed written consent.

Exclusion Criteria:

* Inability to give informed written consent.
* Symptomatic or complicated varicose veins not attributable to SFJ/LSV reflux.
* Evidence of deep venous reflux on duplex scan.
B: Inclusion Criteria:

1. Enrolled in the VeClose study.
2. Able and willing to complete the required 5 year study visit including Duplex ultrasound exam.
3. Able and willing to provide written informed consent prior to study specific data collection.

Exclusion Criteria:

1. Withdrew consent from the VeClose study.
C: Inclusion Criteria:

* Aged 18 or over
* Symptomatic SVI which will likely benefit from treatment in the opinion of an experienced specialist and the participant
* Clinical grades C2-C6 on the CEAP system
* Superficial axial incompetence with proposed treatment lengths of at least 10cm
* Treatment with either endovenous laser ablation or mechanochemical ablation is technically feasible in the view of an experienced endovenous specialist
* Patient is willing to participate (including acceptance of randomisation to either treatment) and give valid, informed consent in the English language

Exclusion Criteria:

* One of the treatments is thought to be preferable by either the patient or an experienced endovenous specialist
* Unwilling or inability to comply with the requirements for follow-up visits
* Known allergy to medications or dressings used in the treatment
* Known right to left circulatory shunt
* Evidence of acute deep venous thrombosis or complete ipsilateral occlusion
* Pelvic vein insufficiency
* Active or recent thrombophlebitis (within 6 weeks)
* Impalpable foot pulses with an Ankle-Brachial Pressure Index of less than 0.8
* Pregnancy or breast feeding
* Active malignancy
* Immobility
* Involvement in other CTIMP trials within the last 6 months
D: Inclusion Criteria:

* age between 18 and 80 years old
* venous ulcer appeared at least 4 weeks, bellow knee
* ankle-brachial index more than 0.9
* saphenous veins insufficiency plus perforating veins reflux
* saphenous vein diameter between 5 mm and 12 mm
* absence of saphenous veins thrombophlebitis
* absence of personal history of venous deep thrombosis
* absence of ultrasound evidence of actual or previous venous deep thrombosis
* absence of severe ankle anquilosis

Exclusion Criteria:

* Unable to provide informed consent
* Unable to receive surgical intervention due to severe clinical condition

Answer: B